MedTrace Logo

Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission

NCT00213083 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6203

Last updated 2017-08-15

No results posted yet for this study

Summary

The purposes of this study are to determine whether Carraguard® Gel can prevent the transmission of HIV when used during vaginal intercourse, and to confirm that the gel is safe for vaginal use.

Conditions

  • HIV Infections
  • AIDS
  • Sexually Transmitted Diseases
  • HIV Seroconversion

Interventions

DRUG

Carraguard (PC-515)

Sponsors & Collaborators

  • United States Agency for International Development (USAID)

    collaborator FED

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Population Council

    lead OTHER

Principal Investigators

  • Pekka Lahteenmaki, MD, PhD · Population Council, Center for Biomedical Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00213083 on ClinicalTrials.gov